Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 66.4 8.1 816.8% View Chart
P/BV x 14.6 2.0 734.7% View Chart
Dividend Yield % 0.4 0.5 72.8%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-21
AUROBINDO PHARMA
Mar-21
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,9131,023 382.5%   
Low Rs1,824333 547.2%   
Sales per share (Unadj.) Rs262.5422.8 62.1%  
Earnings per share (Unadj.) Rs74.792.0 81.3%  
Cash flow per share (Unadj.) Rs84.4110.0 76.7%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Avg Dividend yield %0.70.6 118.2%  
Book value per share (Unadj.) Rs350.1374.3 93.5%  
Shares outstanding (eoy) m265.47585.94 45.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x10.91.6 681.2%   
Avg P/E ratio x38.47.4 520.4%  
P/CF ratio (eoy) x34.06.2 551.3%  
Price / Book Value ratio x8.21.8 452.1%  
Dividend payout %26.84.3 615.2%   
Avg Mkt Cap Rs m761,517397,398 191.6%   
No. of employees `000NANA-   
Total wages/salary Rs m8,25835,350 23.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m69,694247,746 28.1%  
Other income Rs m6263,809 16.4%   
Total revenues Rs m70,320251,555 28.0%   
Gross profit Rs m28,61281,480 35.1%  
Depreciation Rs m2,55610,554 24.2%   
Interest Rs m21745 2.8%   
Profit before tax Rs m26,66073,990 36.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,81820,098 33.9%   
Profit after tax Rs m19,84353,892 36.8%  
Gross profit margin %41.132.9 124.8%  
Effective tax rate %25.627.2 94.1%   
Net profit margin %28.521.8 130.9%  
BALANCE SHEET DATA
Current assets Rs m67,906198,235 34.3%   
Current liabilities Rs m17,284106,652 16.2%   
Net working cap to sales %72.637.0 196.5%  
Current ratio x3.91.9 211.4%  
Inventory Days Days1019 49.6%  
Debtors Days Days87852 1,701.2%  
Net fixed assets Rs m45,963135,778 33.9%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m92,415218,713 42.3%   
Net worth Rs m92,946219,299 42.4%   
Long term debt Rs m01,684 0.0%   
Total assets Rs m113,869334,013 34.1%  
Interest coverage x1,270.5100.3 1,266.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 82.5%   
Return on assets %17.416.4 106.6%  
Return on equity %21.324.6 86.9%  
Return on capital %28.733.8 84.9%  
Exports to sales %053.8 0.0%   
Imports to sales %016.4 0.0%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs mNA40,615 0.0%   
Fx inflow Rs m0133,248 0.0%   
Fx outflow Rs m044,946 0.0%   
Net fx Rs m088,302 0.0%   
CASH FLOW
From Operations Rs m19,46933,289 58.5%  
From Investments Rs m7515,987 12.5%  
From Financial Activity Rs m-349-13,648 2.6%  
Net Cashflow Rs m19,87225,831 76.9%  

Share Holding

Indian Promoters % 52.0 48.8 106.5%  
Foreign collaborators % 0.0 3.1 -  
Indian inst/Mut Fund % 37.2 38.4 96.9%  
FIIs % 20.6 23.7 86.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 48.2 99.8%  
Shareholders   193,883 243,315 79.7%  
Pledged promoter(s) holding % 0.0 22.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   BH.IMMUN&BIO  AMRUTANJAN HEALTHCARE  S.S.ORGANICS  CORAL LAB.  ALPA LAB  



Today's Market

Sensex Slumps 700 Points from Day's High to End Lower; Tata Steel & SBI Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DIVIS LABORATORIES 2020-21 Annual Report Analysis (Annual Result Update)

Aug 12, 2021 | Updated on Aug 12, 2021

Here's an analysis of the annual report of DIVIS LABORATORIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY22); Net Profit Up 13.2% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, DIVIS LABORATORIES has posted a net profit of Rs 6 bn (up 13.2% YoY). Sales on the other hand came in at Rs 20 bn (up 13.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

DIVIS LABORATORIES Announces Quarterly Results (4QFY21); Net Profit Up 29.3% (Quarterly Result Update)

Jun 28, 2021 | Updated on Jun 28, 2021

For the quarter ended March 2021, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 29.3% YoY). Sales on the other hand came in at Rs 18 bn (up 28.7% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider(Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore(Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market(Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race(Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

Revenge Travel is Here. 9 Stocks Likely to Benefit(Views On News)

Sep 4, 2021

The term 'revenge travel' refers to the desire of going on a vacation after an extended period of lockdown.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 17, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS